Hong Kong Stock Announcement Nuggets | Zhongji Innox: The offering price has been determined to be HK$980 per H share

Important matters:

Zhongji Xuchuang (03308): The offering price has been determined to be HK$980 per H share

Hengrui Pharmaceutical (01276): HR-4375 injection for pancreatic cancer treatment has been certified as an orphan drug by the US FDA

Goli Pharmaceutical-B (01672): The GLP-1R/GIPR/GCGR three-target agonist polypeptide ASC37 was injected subcutaneously once a month to show superior weight loss effects in a mouse model of diet-induced obesity

China Biopharmaceutical (01177) and Tempo Scan establish a strategic joint venture to further enhance the accessibility of innovative drugs in Indonesia

Hebo Pharmaceutical-B (02142) signed a strategic cooperation agreement with Sinopharm Group to establish the Sinopharm Group-Hebo Pharmaceutical Innovation Consortium

Basic Semiconductors (09971): Proposed construction of a silicon carbide module packaging production line

YunZhisheng (09678): The big voice model U2-ASR and U2-TTS have been fully upgraded

Dongpeng Drinks (09980) plans to establish a wholly-owned subsidiary in the Zhengzhou Economic and Technological Development Zone to promote and implement the “Dongpeng Drinks Zhengzhou Production Base Project”

Yunzhihui Technology (01037)'s controlling interest will change its owner to receive a premium of about 55.46% from Hon Hai and a full purchase offer

Wanguo Gold Group (03939) clarifies the partial landslide incident at the Jinling Gold Mine: there were no casualties and the mining operation was carried out as usual

Operating performance:

China Energy Construction (03996) signed a new contract amount of 513.188 billion yuan in the first half of the year, a year-on-year decrease of 33.81%

Shiyao Group (01093) Fa Yingxi expects a significant year-on-year increase in comprehensive profit attributable to shareholders of about 5.9 billion yuan to 6.2 billion yuan in the medium term

Old Shop Gold (06181) Fa Yingxi expects mid-term adjusted net profit of about 4.31 billion yuan to 4.36 billion yuan, an increase of about 83% to 85% year-on-year

Sihuan Pharmaceutical (00460) Fa Yingxi expects net profit to increase by no less than 217.2% year-on-year in the first half of the year

Sinopec Guande (00934)'s profit attributable to shareholders is expected to fall by about 25%-35% year-on-year

Ketuo Co., Ltd. (02272) expects to achieve adjusted net profit of about 27 million to 31 million yuan in the first half of the year

Extreme Perspective (06636) predicts that adjusted net profit for the medium term will be up to about 6 million yuan, turning a year-on-year loss into a profit